Introduction to Eye90 Microspheres Clinical Trial
The University of Missouri School of Medicine and MU Health Care have achieved a significant milestone in cancer treatment innovation by launching their first clinical trial using advanced radiopharmaceutical therapy manufactured directly on campus. This groundbreaking initiative represents a major advancement in the university’s research capabilities, demonstrating the complete journey from radiopharmaceutical development and rigorous testing to actual human clinical trials.
Working in close collaboration with ABK Biomedical, cancer researchers at the School of Medicine successfully enrolled their first patient in this pioneering human clinical trial at MU Health Care’s renowned Ellis Fischel Cancer Center. Treatment using Eye90 microspheres® officially began on February 9, marking a historic moment for both the institution and cancer care advancement. This clinical trial signifies a transformative step forward as Mizzou strategically expands its capabilities to conduct sophisticated radiopharmaceutical clinical trials through collaboration with the NextGen Precision Health initiative.
Revolutionary Technology for Liver Cancer Treatment
Eye90 microspheres represent cutting-edge technology in targeted cancer therapy. These specialized radiopaque glass beads are embedded with the radioisotope yttrium-90 (Y-90), specifically designed to treat unresectable liver tumors, including hepatocellular carcinoma and metastatic colorectal cancer. The treatment offers hope to patients whose tumors cannot be removed through conventional surgical procedures.
What distinguishes Eye90 from other therapeutic options is its innovative engineering for precise visualization during the delivery process. This unique design empowers interventional radiologists and oncologists to accurately target liver tumors with highly localized radiation therapy. The approach aims to significantly enhance treatment efficacy while simultaneously minimizing radiation exposure to surrounding healthy tissue, reducing potential side effects and improving patient outcomes.
Campus Research Reactor Drives Innovation
The University of Missouri Research Reactor (MURR) plays a crucial role in this advancement, serving as the only domestic source of Y-90 in the United States. MURR creates the microspheres specifically for ABK Biomedical, establishing the university as an essential contributor to cancer treatment innovation nationwide. This unique capability positions Mizzou at the forefront of radiopharmaceutical production and research.
“Our collaborations with companies like ABK Biomedical are advancing the care and treatment of cancer patients right here in Columbia, as well as patients across the country and around the world,” explained Matt Sanford, executive director of MURR. “We are proud to support ground-breaking advancements in nuclear medicine. By leveraging our expertise in radioisotope production, we are helping bring innovative cancer treatments from laboratory to the clinic, offering new hope for cancer patients.”
Expert Perspectives on Targeted Radiotherapy
Medical professionals involved in the trial express considerable enthusiasm about its potential impact on patient care and treatment outcomes.
“While we participate in many different clinical studies, this is the first radiopharmaceutical clinical trial for Ellis Fischel,” stated Ryan Davis, associate professor of clinical radiology in Mizzou’s School of Medicine and on-site study coordinator. “Studies like this provide early availability of therapies for our patients, and they continue our leadership in translational research. We are excited to be part of this study because we recognize the growing significance of targeted radiotherapy for metastatic tumors.”
Historic Partnership and Microsphere Development
Mizzou has established itself as a pioneer in the development and production of glass microspheres for Y-90 therapy since the 1980s. The first microsphere treatment, TheraSphere, emerged through an innovative collaboration between Delbert Day from Missouri University of Science & Technology (formerly University of Missouri-Rolla) and Gary Ehrhardt from MURR. Together, they combined their specialized ceramic and nuclear chemistry expertise to create revolutionary radioactive glass beads.
TheraSphere received full FDA approval in 2021, and MURR continues to maintain its position as the only U.S. producer today. For the new Eye90 technology, ABK Biomedical partnered with MURR to irradiate and process their microspheres on-site, establishing reliable capability to provide necessary doses for both preclinical and clinical trials.
Comprehensive Preclinical Research Foundation
Mizzou researchers conducted extensive effectiveness and safety studies for Eye90 microspheres that ultimately made the human clinical trial possible. ABK Biomedical funded research and preclinical trials conducted by Jeffrey Bryan, professor of oncology in Mizzou’s College of Veterinary Medicine and associate director of comparative oncology at Ellis Fischel Cancer Center.
Bryan served as the principal investigator on initial small animal model studies, demonstrating that the microspheres performed effectively in living animals. He subsequently led a clinical trial in dogs with hepatocellular carcinoma, partnering with Davis to treat companion animals who had developed liver tumors. Treatment effectiveness and safety were carefully monitored, and the animals underwent imaging using advanced scanning equipment at the MU Veterinary Health Center’s PET Imaging Center.
Future Outlook and Patient Benefits
The Mizzou clinical trial forms part of a broader comprehensive effort to evaluate the safety and effectiveness of Eye90 microspheres in patients with unresectable liver tumors. The study protocol involves a single administration of the microspheres, followed by an extensive year-long monitoring period to thoroughly assess patient outcomes, including tumor response metrics and quality of life measures.
ABK Biomedical has previously initiated similar studies internationally, with the first patient treated at Auckland Hospital in New Zealand. The ongoing research aims to gather comprehensive data to support regulatory approvals and broader clinical adoption of this promising therapeutic approach.
The innovative therapy represents a significant advancement in treating unresectable liver tumors, including hepatocellular carcinoma and metastatic colorectal cancer. Mizzou and Ellis Fischel remain firmly committed to pioneering advanced treatments and improving patient care through cutting-edge research, innovative collaboration, and dedication to translational medicine excellence.
